Cerebrovascular Health Management
Efficacy of the traditional Chinese medicine NAOAN capsule for primary prevention of stroke in high-risk population
Hongmei Liu, Bin Jiang, Jiuyi Huang, Yunhai Liu, Zhen Hong, Li He, Siyan Zhan, Dongling Sun, Xiaojuan Ru, Haixin Sun, Wenzhi Wang
Published 2018-10-20
Cite as Chin J Health Manage, 2018, 12(5): 415-419. DOI: 10.3760/cma.j.issn.1674-0815.2018.05.006
Abstract
ObjectiveTo evaluate the efficacy of the traditional Chinese medicine NAOAN capsule in primary prevention of stroke in high-risk populations.
MethodsA multicenter, randomized controlled study was performed in community setting, involving 1 088 individuals at high risk of stroke, with cerebrovascular function scores<75 and 10-year Framingham stroke risk ≥ 6%. Subjects were recruited in communities at Beijing, Shanghai, Changsha, and Chengdu communities, through resident committees or the village unit. A total of 559 subjects were randomized into a group treated with the NAOAN capsule, and 529 subjects in an aspirin treatment group. Follow-up was performed every 2 months for 2 years. At the mid-point and end of the intervention, we compared cerebrovascular function differences between the 2 groups.
ResultsDuring the 2-year community trial, 531 subjects in the NAOAN capsule group and 465 in the aspirin group followed the protocol. Cerebrovascular function scores increased from 45.2±19.7 at baseline to 61.7±26.5 after the 2-year trial (t=-12.931, P<0.001) in the NAOAN capsule group, and from 47.2±18.9 at baseline to 53.7±25.1 (t=-5.058, P<0.001) in the aspirin group; greater increases in cerebrovascular function scores were found in the NAOAN capsule group than that in the aspirin group (t=4.906, P<0.001).
ConclusionsCerebrovascular function in individuals at high risk of stroke was improved by taking NAOAN capsule. Cerebrovascular function scores improved more with NAOAN capsules than with aspirin.
Key words:
Stroke; Community medicine; High-risk population; NAOAN capsule; Intervention management
Contributor Information
Hongmei Liu
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
National Office for Cerebrovascular Diseases (CVD) Prevention and Control in China, Beijing 100050, China
Bin Jiang
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
Jiuyi Huang
Shanghai Institute of Cerebral Vascular Diseases Prevention and Cure, Shanghai 201203, China
Yunhai Liu
Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, China
Zhen Hong
Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China
Li He
Department of Neurology, West China Hospital, Sichuan University, Chengdu 610000, China
Siyan Zhan
School of Public Health, Peking University, Beijing 100871, China
Dongling Sun
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
Xiaojuan Ru
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
Haixin Sun
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
Wenzhi Wang
Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
National Office for Cerebrovascular Diseases (CVD) Prevention and Control in China, Beijing 100050, China
